FDA And ESA Safety: A Conversation With Bob Temple And Ellis Unger

The January 6 issue of the New England Journal of Medicine featured another editorial in a continuing series of major FDA communications on regulatory policy. In this case, the subject of the agency's evaluations was the safety of erythropoiesis-stimulating agents (ESAs)